Subscribe     Pay Now

France Project Notice - A Novel Combination Treatment Effective Against All Multidrug-Resistant Pathogens Deemed As A Critical Priority By The WHO


Project Notice

PNR 56524
Project Name A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO
Project Detail Antimicrobial resistance (AMR) due to multidrug-resistant Gram-negative bacteria are an increasingly serious healthcare threat, exacerbated by major economic issues underlying the development of new antibacterial drugs. The effectiveness of ß-lactam antibiotics, the most important class of antibacterial agents, is impaired by the production of ß-lactamase enzymes by drug-resistant bacteria. We are developing a combination of a well-known antibiotic (meropenem) and ANT3310, our proprietary, best-in-class serine-ß-lactamase inhibitor, intended for the treatment of hospital-acquired infections caused by drug-resistant pathogens. Our treatment has been pre-clinically proven to be efficacious against all three pathogens deemed a critical priority by the World Health Organization (WHO). We will conduct three clinical trials and next out-license ANT3310 to a pharmaceutical partner. We expect market approval by 2029 and that ANT3310 will generate over €10bn in sales within 13 years.
Funded By European Union (EU)
Country France , Western Europe
Project Value EUR 23,984,443

Contact Information

Company Name ANTABIO
Web Site https://cordis.europa.eu/project/id/190159682

Tell us about your Product / Services,
We will Find Tenders for you